Structure-activity relationships of yessotoxins in cultured cells

被引:23
|
作者
Ferrari, S
Ciminiello, P
Dell'Aversano, C
Forino, M
Malaguti, C
Tubaro, A
Poletti, R
Yasumoto, T
Fattorusso, E
Rossini, GP
机构
[1] Univ Modena & Reggio Emilia, Dipartimento Sci Biomed, I-41100 Modena, Italy
[2] Univ Naples Federico II, Dipartimento Chim Sostanze Nat, I-80131 Naples, Italy
[3] Univ Trieste, Dipartimento Econ & Merceol Risorse Nat & Prod, I-34127 Trieste, Italy
[4] Ctr Ric Marine, Cesenatico, Italy
[5] Japan Food Res Labs, Tama Labs, Tokyo, Japan
关键词
D O I
10.1021/tx030054x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The structure-activity relationship of yessotoxins (YTX) has been probed by measuring the potency of several YTX analogues to cause the accumulation of a 100 kDa MW fragment of E-cadherin in MCF-7 breast cancer cells. Under our experimental conditions, the EC50 of YTX, the reference compound, was 0.55 nM. The introduction of a methylene unit adjacent to one of the sulfate groups, as is the case with the homoyessotoxin molecule, did not appear to greatly affect the potency of the analogue, as the measured EC50 for this compound was 0.62 nM. The EC50 values we measured for 45-hydroxyhomoyessotoxin and carboxyyessotoxin were about 9.4 and 26 nM, respectively, whereas the EC50 of noroxoyessotoxin, lacking most of the C-9 chain, was about 50 nM. Thus, significant differences in the potencies of YTX analogues were found when structural changes involved the C-9 terminal chain of these compounds, leading to the conclusion that this portion of the molecule is essential for the activity of YTX in MCF-7 cells. A comparison of our findings with available information regarding the potency of YTX and its analogues in other experimental systems shows that the EC50'S we measured for the different compounds are up to 200-fold lower and vary in a wider concentration range. We speculate that YTX effects could involve two separate receptorial systems.
引用
收藏
页码:1251 / 1257
页数:7
相关论文
共 50 条
  • [21] Reinvestigation of the structure-activity relationships of isoniazid
    Hegde, Pooja
    Boshoff, Helena I. M.
    Rusman, Yudi
    Aragaw, Wassihun Wedajo
    Salomon, Christine E.
    Dick, Thomas
    Aldrich, Courtney C.
    TUBERCULOSIS, 2021, 129
  • [22] Structure-activity relationships of ustiloxin analogues
    Joullie, Madeleine M.
    Berritt, Simon
    Hamel, Ernest
    TETRAHEDRON LETTERS, 2011, 52 (17) : 2136 - 2139
  • [23] Visualizing structure-activity relationships in ABCD
    Agrafiotis, DK
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2005, 230 : U1368 - U1369
  • [24] Structure-activity relationships of antiarrhythmic peptides
    Dhein, S
    Grover, R
    Piecha, D
    Tudyka, T
    Kruesemann, K
    Klaus, W
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (04) : R101 - R101
  • [25] STRUCTURE-ACTIVITY RELATIONSHIPS IN NEW PENICILLINS
    ROLLO, IM
    SOMERS, GF
    BIOCHEMICAL PHARMACOLOGY, 1961, 8 (01) : 43 - &
  • [26] Analysis of structure-activity relationships with biosensors
    Van Regenmortel, MHV
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1999, 27 (02) : 329 - 331
  • [27] Information system for structure-activity relationships
    Ihlenfeldt, WD
    NACHRICHTEN AUS DER CHEMIE, 2001, 49 (05) : 659 - 661
  • [28] Structure-activity relationships in complex carbohydrates
    Chaplin, M
    RIGHT FIBRE FOR THE RIGHT DISEASE, 1999, (236): : 11 - 16
  • [29] Structure-activity relationships of the didemnins.
    Katauskas, AJ
    Rinehart, KL
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1997, 213 : 408 - ORGN
  • [30] Structure-Activity Relationships in Oxygen Electrocatalysis
    Han, Jingyi
    Sun, Jingru
    Chen, Siyu
    Zhang, Siying
    Qi, Luoluo
    Husile, Anaer
    Guan, Jingqi
    ADVANCED MATERIALS, 2024, 36 (47)